Novartis: Oddo confirms rating ahead of results
(CercleFinance.com) - Novartis will release its Q2 results on 21 July, which are expected to be impacted by a mechanical slowdown.
Prior to this publication, Oddo confirms its buy rating on the share with a target price of 97 Swiss francs.
At this stage, we do not see any change in the group's guidance for the current year, with sales growth of between 5% and 9% and between 7% and 12% growth in Core EBIT at constant exchange rates, Oddo says.
H2 should be more dynamic, with the results of Lu-PSMA-617 in prostate cancer and asciminib in leukemia (CML), Oddo adds.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Prior to this publication, Oddo confirms its buy rating on the share with a target price of 97 Swiss francs.
At this stage, we do not see any change in the group's guidance for the current year, with sales growth of between 5% and 9% and between 7% and 12% growth in Core EBIT at constant exchange rates, Oddo says.
H2 should be more dynamic, with the results of Lu-PSMA-617 in prostate cancer and asciminib in leukemia (CML), Oddo adds.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.